Walethmade%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrrolate) ## Overview Walethmade bromide is the brand name for **Glycopyrrolate**, a synthetic quaternary ammonium anticholinergic agent. It does not cross the blood-brain barrier effectively, resulting in fewer central nervous system side effects compared to atropine or scopolamine. ## Primary Indications * Reduction of secretions (preoperative). * Reversal of neuromuscular blockade (in combination with neostigmine). * Management of peptic ulcer disease (adjunctive therapy, though rarely used for this purpose now). * Reduction of pathologic drooling (sialorrhea) in pediatric cerebral palsy or neurological conditions. ## Adult Dosing * **Preoperative Anticholinergic:** 0.004 mg/kg IM 30–60 minutes prior to anesthesia. * **Reversal of Neuromuscular Blockade:** 0.2 mg for every 1 mg of neostigmine administered. * **Peptic Ulcer:** 1 mg PO TID or 2 mg PO BID; may titrate up to 8 mg/day. ## Pediatric Dosing * **Preoperative:** 0.004–0.01 mg/kg IM/IV (max 0.1–0.2 mg/dose). * **Chronic Sialorrhea (Oral Solution):** Based on weight. * 13–17 kg: 1.5 mL (0.9 mg) TID. * 18–27 kg: 2.0 mL (1.2 mg) TID. * 28–37 kg: 2.5 mL (1.5 mg) TID. * >38 kg: 3.0 mL (1.8 mg) TID. * *Note: Always verify strength (typically 1 mg/5 mL) to ensure accurate dosing.* ## Dose Adjustments * **Renal Impairment:** Reduce dose or increase interval in severe renal impairment (CrCl <30 mL/min), as glycopyrrolate is primarily excreted renally. * **Hepatic Impairment:** No standard adjustments; use with caution. ## Contraindications * Glaucoma (narrow-angle). * Obstructive uropathy (e.g., prostatic hypertrophy). * Obstructive GI disease (e.g., pyloric stenosis, paralytic ileus). * Myasthenia gravis (unless targeting muscarinic side effects of cholinergic therapy). * Tachycardia secondary to cardiac insufficiency/thyrotoxicosis. ## Adverse Effects * **Common:** Dry mouth (xerostomia), constipation, urinary retention, blurred vision, tachycardia, and flushed skin. * **Serious:** Heat prostration (due to decreased sweating), cognitive impairment (rare, but can occur in sensitive populations/elderly), and palpitations. ## Key Drug Interactions * **Potentiation:** Increased anticholinergic effect when combined with tricyclic antidepressants, antihistamines, antipsychotics, and other antispasmodics. * **GI Absorption:** May decrease absorption of slowly dissolving oral medications. * **Potassium Chloride:** Solid oral dosage forms of KCl may have increased risk of GI ulceration when administered with anticholinergics due to prolonged transit time. ## Monitoring * Heart rate and rhythm (especially post-reversal). * Intake and output (assess for urinary retention). * Bowel function (assess for constipation/ileus). * Severity of secretions (for sialorrhea patients). ## Clinical Pearls * Glycopyrrolate is preferred over atropine in "at-risk" cardiac patients because it is less likely to induce tachycardia. * For sialorrhea, administer 1 hour before or 2 hours after meals (high-fat meals can significantly alter absorption). * Patients with autonomic neuropathy may have an exaggerated response to glycopyrrolate. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, indications, and safety protocols vary by institution and patient-specific factors. Always verify current prescribing information—including the manufacturer's package insert and hospital-specific formulary guidelines—before prescribing or administering medication.